A Phase 2 interventional study of Tasimelteon and Placebo in Jet Lag Disorder, sponsored by Vanda Pharmaceuticals. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-03.
Sponsored by Vanda Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
tasimelteon, administered as oral capsule(s)
Drug: Tasimelteon
Placebo, administered as oral capsule(s)
Drug: Placebo
capsule
capsule
Total Sleep Time in the First Two-Thirds of the Night on the Night(s) Most Likely to be Disrupted
Measured using polysomnography (PSG) and analyzed as change from baseline. Examination of the observational phase baseline data demonstrated that Night 3 was the night most disrupted.
Time frame: 4 days
Patient Global Impression of Severity (PGI-S) Day 4
Self-reported global index measure analyzed as change from baseline. The baseline was the corresponding measurement in the screening flight. The PGI-S is a single question asking the subject to rate their jet-lag condition at the present time on a scale of 1 "Normal" to 4 "Severe".
Time frame: 1 Day
Total Sleep Time in the First Two-Thirds of the Night (All 3 Nights)
Measured using polysomnography (PSG) and analyzed as change from baseline. The baseline was the corresponding measurement in the screening flight.
Time frame: 3 Days
Subjective Total Sleep Time on Night 3
Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline
Time frame: 1 Day
Subjective Sleep Quality Night 3
Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline. Sleep quality was ranked from 1 "Poor" to 5 "Excellent" and was the subscale of the post-sleep questionnaire used to determine subjective sleep quality.
Time frame: 1 Day
Subjective Sleep Latency Night 3
Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline
Time frame: 1 Day
Subjective Wake After Sleep Onset Night 3
Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline
Time frame: 1 Day
Karolinska Sleepiness Scale Day 4
Self-reported fatigue measure analyzed as change from baseline. The baseline was the corresponding measurement in the screening flight. The KSS is a single question asking the subject to rate how sleepy they feel at that moment on a 9-point scale where 1 = extremely awake and 9 = extremely sleepy/fighting to stay wake.
Time frame: 1 Day
| Milestone | Tasimelteon | Placebo |
|---|---|---|
| Started | 13 | 12 |
| Completed | 13 | 12 |
| Not completed | 0 | 0 |
Measured using polysomnography (PSG) and analyzed as change from baseline. Examination of the observational phase baseline data demonstrated that Night 3 was the night most disrupted.
| minutes | Tasimelteon | Placebo |
|---|---|---|
| Total Sleep Time in the First Two-Thirds of the Night on the Night(s) Most Likely to be Disrupted | 76.2 ± 11.213 | 41.4 ± 11.882 |
Self-reported global index measure analyzed as change from baseline. The baseline was the corresponding measurement in the screening flight. The PGI-S is a single question asking the subject to rate their jet-lag condition at the present time on a scale of 1 "Normal" to 4 "Severe".
| units on a scale | Tasimelteon | Placebo |
|---|---|---|
| Patient Global Impression of Severity (PGI-S) Day 4 | -0.71 ± 0.174 | -0.07 ± 0.183 |
Measured using polysomnography (PSG) and analyzed as change from baseline. The baseline was the corresponding measurement in the screening flight.
| Minutes | Tasimelteon | Placebo |
|---|---|---|
| Total Sleep Time in the First Two-Thirds of the Night (All 3 Nights) | 131.4 ± 35.243 | 40.9 ± 37.774 |
Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline
| Minutes | Tasimelteon | Placebo |
|---|---|---|
| Subjective Total Sleep Time on Night 3 | 111.9 ± 23.012 | 33.47 ± 24.555 |
Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline. Sleep quality was ranked from 1 "Poor" to 5 "Excellent" and was the subscale of the post-sleep questionnaire used to determine subjective sleep quality.
| units on a scale | Tasimelteon | Placebo |
|---|---|---|
| Subjective Sleep Quality Night 3 | 1.31 ± 0.273 | 0.36 ± 0.290 |
Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline
| Minutes | Tasimelteon | Placebo |
|---|---|---|
| Subjective Sleep Latency Night 3 | -20.6 ± 8.39 | 6.0 ± 8.76 |
Measured using the post-sleep questionnaire on Day 4 and analyzed as change from baseline
| Minutes | Tasimelteon | Placebo |
|---|---|---|
| Subjective Wake After Sleep Onset Night 3 | -81.1 ± 22.53 | -24.7 ± 24.01 |
Self-reported fatigue measure analyzed as change from baseline. The baseline was the corresponding measurement in the screening flight. The KSS is a single question asking the subject to rate how sleepy they feel at that moment on a 9-point scale where 1 = extremely awake and 9 = extremely sleepy/fighting to stay wake.
| units on a scale | Tasimelteon | Placebo |
|---|---|---|
| Karolinska Sleepiness Scale Day 4 | -1.69 ± 0.388 | -0.69 ± 0.409 |
Collected over 15 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tasimelteon | 0/13 (0%) | 0/13 (0%) | 7/13 (53.8%) |
| Placebo | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Event | Tasimelteon | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 4/13 | 4/12 |
| VomitingGastrointestinal disorders | 2/13 | 0/12 |
| NauseaGastrointestinal disorders | 0/13 | 1/12 |
| MalaiseGeneral disorders | 0/13 | 1/12 |
| NasopharyngitisInfections and infestations | 0/13 | 1/12 |
| DehydrationMetabolism and nutrition disorders | 0/13 | 1/12 |
| Skin irritationSkin and subcutaneous tissue disorders | 0/13 | 1/12 |
| Ear discomfortEar and labyrinth disorders | 1/13 | 0/12 |
| Age, Continuous(years) | Tasimelteon | Placebo | Total |
|---|---|---|---|
| Mean | 51.3 ± 13.47 | 48.2 ± 16.06 | 49.8 ± 14.54 |
| Sex: Female, Male(Participants) | Tasimelteon | Placebo | Total |
|---|---|---|---|
| Female | 9 | 6 | 15 |
| Male | 4 | 6 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Tasimelteon | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 12 | 12 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Tasimelteon | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 4 |
| White | 10 | 6 | 16 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Tasimelteon | Placebo | Total |
|---|---|---|---|
| United States | 13 | 12 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2016 to primary completion in Nov 2017, 16 months.
Results were first posted in Nov 2021, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tasimelteon